Roivant Sciences
8
62M
6
1.00
2
0.25
2
- Areas of investment
Summary
In 2014 was created Roivant Sciences, which is appeared as Corporate Investor. The company was established in Europe in Switzerland. The leading representative office of defined Corporate Investor is situated in the Basel.
The fund has no exact preference in some founders of portfolio startups. Among the most successful fund investment fields, there are Data Integration, Clinical Trials. Among the most popular portfolio startups of the fund, we may highlight Datavant, Arbutus Biopharma. Moreover, a startup needs to be at the age of 11-15 years to get the investment from the fund. For fund there is no match between the country of its foundation and the country of its the most frequent investments - Canada.
The current fund was established by Vivek Ramaswamy.
The usual cause for the fund is to invest in rounds with 3 partakers. The meaningful sponsors for the fund in investment in the same round are Travis May, Tom Chavez, SoftBank Investment Advisers.
The important activity for fund was in 2017. The higher amount of exits for fund were in 2010. The fund is constantly included in less than 2 investment rounds annually. Deals in the range of 50 - 100 millions dollars are the general things for fund.
Investments analytics
Analytics
- Total investments
- 8
- Lead investments
- 2
- Exits
- 2
- Rounds per year
- 1.00
- Follow on index
- 0.25
- Investments by industry
- Biopharma (4)
- Health Care (3)
- Genetics (3)
- Biotechnology (3)
- Pharmaceutical (3) Show 11 more
- Investments by region
-
- United States (5)
- Canada (2)
- Brazil (1)
- Peak activity year
- 2021
Discover reliable insights
Leverage validated data, identify key contacts and secure funding opportunities for your business.Quantitative data
- Avg. startup age at the time of investment
- 7
- Avg. valuation at time of investment
- 52M
- Group Appearance index
- 0.50
- Avg. company exit year
- 2
Need more data?
Get access to full data about investors, including their team, contact information, and historic data.
Latest deals
| Company name | Deal date | Industry | Deal stage | Deal size | Location |
|---|---|---|---|---|---|
| Lokavant | 07 Dec 2022 | Artificial Intelligence, Risk Management, Data Visualization | Early Stage Venture | 21M | United States, New York, New York |
At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).
Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.